ライフサイエンスコーパス: infusion rate

1 evel orientation, insertion rate, depth, and infusion rate).

2 for the 100-200 microu (kg body weight)(-1) infusion rates).

3 matrix calcium loads that are independent of infusion rate.

4 and usually responded to adjustments in the infusion rate.

5 aximal (240 pmol x kg(-1) x min[-1]) insulin infusion rate.

6 findings do not support the use of a slower infusion rate.

7 after 1 hr of propofol at the same previous infusion rate.

8 F patients were examined at increasing 3-OHB infusion rates.

9 ol/l; P = 0.009), despite matched intralipid infusion rates.

10 n rate and was not increased at the 2 lowest infusion rates.

11 ere then compared with the known intraportal infusion rates.

12 performed in 22 infants given feedings at 2 infusion rates.

13 he brain decreases exponentially with faster infusion rates.

14 concentrations in patients receiving similar infusion rates.

15 ulation of </= 78 pg/ml, even at the highest infusion rates.

16 fibrillation (9.5% with 50 mL/min) at higher infusion rates.

17 to 1.27 mg/kg/h at a steady dexmedetomidine infusion rate (0.54 mug/kg/h) was associated with reduce

18 combined with indirect calorimetry (insulin infusion rate (1.5 mU x kg-1 x min-1)) in 12 male patien

19 nd p.m., both between 5:00 and 8:00, insulin infusion rate 10 mU/m2/min) (study 2).

20 were more insulin resistant (median glucose infusion rate 10.1 vs. 18.9 mg/kglean/min; P < 0.0001) a

21 h euglycemic-hyperinsulinemic clamp (insulin infusion rate = 100 mU x m(-2) x min(-1)), and a 75-g OG

22 es resulted in significantly greater glucose infusion rates (16 +/- 2 vs. 6 +/- 2 and 6 +/- 3 micro m

23 omol x kg[-1] x min[-1]) and maximal insulin infusion rate (240 micromol x kg[-1] x min[-1]).

24 ats/min after TMLR, p = 0.01) and dobutamine infusion rate (26 +/- 9 micrograms/kg body weight per mi

25 The insulin infusion rate (4 mU.kg(-1).min(-1)) was selected to matc

26 A2) were infused with intralipid at a higher infusion rate (44%) to match the arterial concentrations

27 d to receive fluid challenges at 2 different infusion rates; 5538 to the slower rate (333 mL/h) and 5

28 , SIT increased insulin sensitivity (glucose infusion rate: 6.3 +/- 0.6 vs. 8.0 +/- 0.8 mg kg(1) min(

29 would be required to inject the bolus at the infusion rate = 60 min), and arterial blood was collecte

30 Elimination of VUR required a slowed infusion rate, a reduced inoculum volume (25 microliter)

31 The glucose infusion rate (adjusted for fat free mass and circulatin

32 r patients at hospitals with higher inotrope infusion rates (adjusted odds ratio [AOR], 1.98; 95% CI,

33 nemic euglycemic clamping, showing a glucose infusion rate among carriers 2 times that among controls

34 greater when given at a slow than at a fast infusion rate, an effect more pronounced for albumin.

35 sitivity, as indicated by 42% higher glucose infusion rate and 90% greater muscle [(3)H]-2-deoxygluco

36 and cardiac index beginning with the lowest infusion rate and achieving maximal increases in stroke

37 GF6A required a significantly higher glucose infusion rate and demonstrated higher insulin levels dur

38 48% reduction of insulin-stimulated glucose infusion rate and glucose clearance, respectively.

39 Glucose infusion rate and leg glucose extraction during the clam

40 Glucose infusion rate and leg glucose uptake was decreased by in

41 amp studies showed a 75% decrease in glucose infusion rate and markedly reduced 2-deoxyglucose uptake

42 d from distension responses by adjusting the infusion rate and opening or closing the drainage port i

43 may be predicted by the high-dose lorazepam infusion rate and osmol gap.

44 cant correlation between high-dose lorazepam infusion rate and serum propylene glycol concentrations

45 DIO mice revealed that MTZ increased glucose infusion rate and suppressed endogenous glucose producti

46 prior report, GCGR agonism increased glucose infusion rate and suppressed hepatic glucose production

47 The relationship between the norepinephrine infusion rate and the use of beta-blockers and plasma cy

48 venous bolus dose, when given, and diltiazem infusion rate and time necessary to achieve the target h

49 rate increased modestly (8%) at the maximal infusion rate and was not increased at the 2 lowest infu

50 U/kg/min) and maximal (25 mU/kg/min) insulin infusion rates and demonstrated the presence of insulin

51 TS-As expected, diazoxide suppressed glucose infusion rates and increased glucagon and epinephrine re

52 The changes in glucose infusion rates and plasma insulin levels demonstrate an

53 By tweaking fluid infusion rates and pneumatic pressures and maintaining c

54 correct flow-sheet charting, concentration, infusion rate, and dose administered, as well as patient

55 ltage, heated capillary temperature, solvent infusion rate, and solvent composition, are evaluated an

56 concentration four-fold compared to the same infusion rate at normothermia, leading to increased syst

57 were used: 1) euglycemic clamp with insulin infusion rates at 40, 120, 300, and 1,200 mU / m / min c

58 annula reflux (which permitted corresponding infusion rate/cannula adjustments).

59 n examinations performed with contrast agent infusion rates compatible with or higher than those of h

60 r IgMIg administration, median noradrenaline infusion rates could be significantly reduced from 1.6 m

61 Slower intravenous fluid infusion rates could reduce the formation of tissue edem

62 analyses adjusted for age and norepinephrine infusion rate demonstrated that the combination of highe

63 In patients with HF, sitaxsentan caused an infusion rate-dependent decrease in local PVR (P<0.05 ve

64 ]; dopamine OR, 0.87 [95% CI, 0.59-1.28]) or infusion rate (dobutamine OR, 1.50 [95% CI, 0.99-1.02];

65 h peak levels of dopamine were unaffected by infusion rate, dopamine levels increased more rapidly wh

66 The glucose infusion rate during a hyperinsulinemic-euglycemic clamp

67 btracting the integrated decrease in glucose infusion rate during the 4 h after glucose ingestion fro

68 btracting the integrated decrease in glucose infusion rate during the 4-h period after glucose ingest

69 glucose ingestion, the steady-state glucose infusion rate during the insulin clamp was decreased app

70 glucose ingestion, the steady-state glucose infusion rate during the insulin clamp was decreased app

71 ever, there are no data to support different infusion rates during fluid challenges for important out

72 Glucose infusion rates during hyperinsulinemic-hyperglycemic cla

73 male alphaZnT8KO mice required lower glucose infusion rates during hypoglycemic clamps and displayed

74 However, when infusion rates exceeded 20 ul/kg/min, signs of injury oc

75 eady-state concentrations at even the lowest infusion rate exceeding endogenous concentrations by at

76 (-1) and maintained at the maximal tolerated infusion rate for an additional 2 hours.

77 ibody; reactions were reduced by slowing the infusion rate for later patients.

78 nsus on the ideal intravenous fluid type and infusion rate for optimal patient outcomes remains elusi

79 The infusion rate for patients receiving cisatracurium was 3

80 The starting infusion rate for subcutaneous fentanyl varied from 5 to

81 ng effect was better with a slow than a fast infusion rate for the colloids, especially albumin, but

82 Much higher infusion rates for CNP (50 microg/kg/min), which yielded

83 lication of propofol use, especially at high infusion rates for prolonged periods.

84 1.0, and 0.17 mg/min, respectively; constant infusion rates for V and I of 0.2 and 0.3 mg/min, respec

85 e, 5-min microdialysis samples (2 microl/min infusion rate) from amygdala and locus ceruleus complex

86 hip between steady state glucose and glucose infusion rate (GE[CLAMP(total)]), Rd (GE[CLAMP(uptake)])

87 , as reflected by a markedly reduced glucose infusion rate (Ginf) during the clamp (21.4 +/- 2.3 vs.

88 LPL haplotypes showed linkage to the glucose infusion rate (GINF), a direct physiologic measurement o

89 Glucose infusion rates (Ginf) decreased significantly in the Lip

90 l-NMMA injection also increased the glucose infusion rate (GIR) and decreased epinephrine secretion

91 in-KO mice required a 10-fold higher glucose infusion rate (GIR) and exhibited less robust corticoste

92 -1 or insulin markedly increased the glucose infusion rate (GIR) by >50% and suppressed HGP (P < 0.00

93 to 32 and 49%, respectively, in the glucose infusion rate (GIR) in the hyperinsulinemic euglycemic c

94 in secretion, insulin clearance, and glucose infusion rate (GIR) needed to maintain hyperglycemia.

95 In the latter, the glucose infusion rate (GIR) required to maintain euglycemia (40.

96 ring the hyperinsulinemic clamp, the glucose infusion rate (GIR) required to maintain euglycemia and

97 tors explaining observed variance in glucose infusion rate (GIR).

98 ent was not paralleled by reduced HG glucose infusion rate (GIR).

99 d slower acquisition of steady-state glucose infusion rates (GIR) after a 5-h fast.

100 ated SU rats were insulin-resistant (glucose infusion rate [GIR] = 14.5 +/- 1.1 mg.kg(-1).min(-1)); m

101 Glucose infusion rates (GIRs) during the last 30 min of the clam

102 Glucose infusion rates (GIRs) had to be increased more after nas

103 tic glucose balance, calculated when glucose infusion rates (GIRs) were ~20 micromol kg(-1) min(-1) i

104 The same infusion rates given through 1 end hole (n=6) or in the

105 ies revealed a dramatically improved glucose infusion rate, glucose disposal rate, and hepatic glucos

106 lycemic plateaus by variable labeled glucose infusion rate; glucose effectiveness (GE) was quantified

107 Using the same infusion rate, glutamate or denatonium solutions produce

108 er minute]) and insulin sensitivity (glucose infusion rate > or = 7.50 mg/kg per minute [range, 7.52

109 The infusion rate, hub pressure, and location were documente

110 lamp study caused a reduction in the glucose infusion rate in nondiabetic rats exposed to recurrent h

111 monitors the EEG and adjusts the anesthetic infusion rate in real time to maintain the specified tar

112 Glucose infusion rate in response to insulin infusion was used t

113 increased as a function of fluid volume and infusion rate in wild-type animals, but W/W(v) animals s

114 ponses, whereas glybenclamide raised glucose infusion rates in conjunction with reduced glucagon and

115 ous and stable system operation is shown for infusion rates in the range of 0.4-1.2 droplets/s, while

116 ortex, and cerebellum were normalized to the infusion rate (in becquerels per hour).

117 e found to be dependent on plasma fatty acid infusion rates, independent of changes in plasma insulin

118 M/I was estimated from steady-state glucose infusion rate/insulin (mg/kg/min) by hyperglycemic clamp

119 At the 0.5 mU x kg(-1) x min(-1) insulin infusion rate, leg FFA release was almost completely sup

120 s used to define insulin resistance (glucose infusion rate < or = 4.00 mg/kg of body weight per minut

121 Lower infusion rates make the studies more likely to accuratel

122 1.1%-16.4%) that improved when corrected for infusion rate (mean, 8.2%-9.9%) or for injected dose (me

123 compared with nondiabetic controls: glucose infusion rate (mg/kg FFM/min) = 6.19 +/- 0.72 vs. 12.71

124 e control subjects, CR increased the glucose infusion rate needed to maintain euglycemia during hyper

125 ion and, consequently, the exogenous glucose infusion rate needed to maintain hypoglycemia were signi

126 insulin sensitivity (i.e., GIR, the glucose infusion rates needed to maintain euglycemia during hype

127 Glucose infusion rate, nonhepatic glucose uptake, and tracer-det

128 d with insulin resistance, with mean glucose infusion rates (normal/fatty liver/NASH) of step 1, 4.5/

129 were uptitrated over 4 hours from an initial infusion rate of 0.1 microg x kg(-1) x min(-1) to a maxi

130 Use of a standard infusion rate of 0.5 mg/kg/min is safe, logical, and the

131 in a rat model of arterial thrombosis at an infusion rate of 10 micrograms/kg/min, exhibits oral bio

132 ctive fashion that 500 mL of 3% saline at an infusion rate of 100 mL per hour can be given safely.

133 With an infusion rate of 120 mL/min, cooling rates for the salin

134 /min and was achieved in 4.8 hrs with a mean infusion rate of 14.8 mg/hr.

135 was infused by a syringe pump at a constant infusion rate of 5 muL/min.

136 rostacyclin was administered at a continuous infusion rate of 5 ng/kg/min for 60 mins.

137 g in 250 mL of 5% dextrose for 45 mins at an infusion rate of 62.5 mL/hr.

138 At the highest infusion rate of acetylcholine (16 microg (100 ml tissue

139 Similarly, at the highest infusion rate of substance P (125 pg (100 ml tissue)(-1)

140 e output measurements were used to guide the infusion rate of the lactated Ringer's.

141 was increased to 75 mm Hg by increasing the infusion rate of the vasoactive agent.

142 Subsequently, the infusion rate of the vasoactive drug was reduced until a

143 fect on the systemic arterial pressure at an infusion rate of up to 24 nmol.kg-1.min-1.

144 andomly assigned and were studied at insulin infusion rates of 0, 20, 40 and 120 mU/min/m2 body surfa

145 f 3 dosing regimens of selepressin (starting infusion rates of 1.7, 2.5, and 3.5 ng/kg/min; n = 585)

146 ly suppressed glycerol appearance at insulin infusion rates of 10 mU. m(-2). min(-1).

147 , ANP failed to lower blood pressure even at infusion rates of 50 microg/kg/min.

148 On an Orbitrap platform droplet infusion rates of 6 Hz are used for analysis of cytochro

149 es: To quantify the association of different infusion rates of dexmedetomidine and propofol, given in

150 tion analysis to produce quartiles of steady infusion rates of dexmedetomidine while escalating propo

151 n double stratification analysis, escalating infusion rates of propofol to 1.27 mg/kg/h at a steady d

152 tracoronary adenosine, and during increasing infusion rates of saline at room temperature through a d

153 ients had a marked depressor response to low infusion rates of trimethaphan; the response in PAF pati

154 Within 8 weeks of infusion, rates of cytokine release syndrome were 48.5%

155 Within 8 weeks of infusion, rates of cytokine release syndrome were 48.5%

156 Larger infusion rates offer no further benefits.

157 n resistance, with a 33% decrease in glucose infusion rate (P < 0.01).

158 a approximately 35% reduction in the glucose infusion rate (P < 0.05 vs. control).

159 gnificant interaction between fluid type and infusion rate (P = .98).

160 y to insulin, evidenced by increased glucose infusion rate (P = 0.077) and significantly increased sk

161 At similar steady-state infusion rates, plasma dopamine concentrations varied ov

162 splayed a significantly higher glucose clamp infusion rate posttreatment (9.1 +/- 1.3 intensive insul

163 th hyperinsulinemic-euglycemic clamp glucose infusion rate (r = -0.28, P < 0.05).

164 Lorazepam infusion rates ranged from 0.1 to 0.33 mg.kg.hr and last

165 Cisatracurium infusion rates ranged from 6.3 to 10.5 microg/kg/min, wi

166 Y) mice, A(2B)R antagonism increased glucose infusion rate, reduced hepatic glucose production, and i

167 asopressors; vasopressor type, duration, and infusion rate; reoperation within the first 5 postoperat

168 Patients were randomized to 2 different infusion rates (reported in this article) and 2 differen

169 on reported in this article) and 2 different infusion rates (reported separately).

170 The glucose infusion rate required to clamp glucose at 65 mg/dl was

171 uglycemic clamp reveals an increased glucose infusion rate required to maintain euglycemia and showed

172 inavir treatment acutely reduced the glucose infusion rate required to maintain euglycemia by 18 and

173 th a 36% reduction (P < 0.05) in the glucose infusion rate required to maintain euglycemia during hyp

174 s reflected by a 25% increase in the glucose infusion rate required to maintain euglycemia during the

175 ipid and lactate infusions decreased glucose infusion rates required to clamp plasma glucose by appro

176 At the lower dose, the exogenous glucose infusion rates required to maintain euglycemia during st

177 The glucose infusion rates required to maintain identical glucose le

178 The glucose infusion rates required to maintain target plasma glucos

179 ximately 30%, as indicated by portal glucose infusion rate (saline 15.9 +/- 1.6 vs. exenatide 20.4 +/

180 ze citrate and will require calcium chloride infusion rates significantly above normal.

181 suppressed, whereas muscimol raised glucose infusion rates significantly compared with controls.

182 In dogs with infusion rates similar to insulin itself, NN304 exhibits

183 n with the 1.0 mU x kg(-1) x min(-1) insulin infusion rate, splanchnic FFA release decreased by only

184 +RH group required a 1.7-fold higher glucose infusion rate than those in the STZ group, consistent wi

185 artery (SPDa) of STZ-administered rats at an infusion rate that did not alter systemic venous glucose

186 ntravenous infusions of rhRLX over 5 h at an infusion rate that was chosen to sustain serum concentra

187 At the highest infusion rates, they exhibited diuresis, dehydration, an

188 At higher infusion rates, they were unable to process further gluc

189 he was ameliorated at 5 mg by prolonging the infusion rate to 20 minutes, but dose-limiting headache

190 (EEG) and manually titrating the anesthetic infusion rate to maintain a specified level of burst sup

191 ch Sur2(-/-) mice required a greater glucose infusion rate to maintain a target blood glucose level.

192 Lastly, the glucose infusion rate to maintain the desired hypoglycemia was s

193 /-) and Adipo(+/+) mice have similar glucose infusion rates to maintain a similar serum glucose.

194 icker animals required higher norepinephrine infusion rates to maintain blood pressure (and higher FI

195 a similar magnitude by insulin, but glucose infusion rates to maintain euglycemia were higher in mut

196 stablish maximum tolerated dose (the highest infusion rate tolerated by at least eight participants)

197 At the insulin infusion rate used, the magnitude of this defect was com

198 The total GLC infusion rate was 14% greater in dogs infused with GLC t

199 Mean infusion rate was 2.8 mL/sec (range, 1-5 mL/sec).

200 Their glucose infusion rate was 30% higher than that of the WT mice in

201 The glucose infusion rate was 44.2 +/- 3.5% higher (P < 0.01) during

202 The median peak infusion rate was 67 microg/kg/min (range, 19-200).

203 The propofol infusion rate was adjusted and repeat loading doses were

204 iable regression, escalating dexmedetomidine infusion rate was associated with increased adjusted mor

205 Indeed, the insulin-stimulated glucose infusion rate was decreased by 12-31%; suppression of he

206 2 hours during reperfusion, after which the infusion rate was halved and an additional 50 mL was giv

207 Glucose infusion rate was identical between groups before treatm

208 glycemic hyperinsulinemic clamp, the glucose infusion rate was improved in LivARKO-DHT mice compared

209 The glucose infusion rate was increased more than 30% in the hyperin

210 ructose on glucose kinetics, average glucose infusion rate was markedly reduced in the fructose infus

211 plication in lean subjects, a higher glucose infusion rate was necessary to maintain euglycemia compa

212 eeks after lesioning showed that the glucose infusion rate was significantly lower in SCN lesioned mi

213 2 h of insulin infusion, whole-body glucose infusion rate was significantly lower in the obese versu

214 The standard infusion rate was then modified to 30 minutes for all be

215 The steady-state glucose infusion rate was threefold higher in the MR group and c

216 om steady-state ICP at different ventricular infusion rates, was not affected by AQP1 deletion.

217 azepam received and mean high-dose lorazepam infusion rate were 8.1 mg/kg (range, 5.1-11.7) and 0.16

218 The 72-hour average insulin infusion rates were 3.37 +/- 0.61 and 4.57 +/- 1.18 U/hr

219 Initial boluses and infusion rates were as follows: lorazepam 0.05 mg/kg, th

220 In patients, higher norepinephrine infusion rates were correlated with a more antiinflammat

221 Infusion rates were determined by caregivers and ranged

222 noted in men than in women, whereas glucose infusion rates were higher in women.

223 ring exercise were also reduced, and glucose infusion rates were increased following prior euglycemia

224 istration of bicuculline methiodide, glucose infusion rates were significantly suppressed, whereas mu

225 al glucose levels during the similar insulin infusion rates were substantially lower in diabetic Indi

226 effects of these identical AICAR and insulin infusion rates were then examined in the obese Zucker ra

227 ated by C-peptide deconvolution) and insulin infusion rates were used as inputs to a new two-compartm

228 us glucose monitors and standardized glucose infusion rates were used to manage hyperglycemia in crit

229 s glucose monitors, and standardized glucose infusion rates were used to minimize hypoglycemia.

230 Consecutive 5-min samples (2 microl/min infusion rate) were obtained from left amygdala and ipsi

231 VDR activation greatly increased the glucose infusion rate, while hepatic glucose production was rema

232 stance with significant increases in glucose infusion rates, whole-body glucose turnover, and skeleta

233 he lower intrinsic activity allowed a higher infusion rate with M5, which induced the most rapid and

234 e but not at 140 mug/kg per minute adenosine infusion rate, with mean difference (95% confidence inte

235 Thus, we hypothesized that glucose infusion rate would be augmented and neuro-hormonal coun